Modified vitamin K-dependent polypeptides
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
1. A mutant Factor VII or VIIa polypeptide that increases clot formation comprising a modified gamma-carboxyglutamic acid (GLA) domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native Factor VII or Factor VIIa polypeptide, said modified GLA domain comprising two to four amino acid substitutions, wherein a glutamine residue is substituted at amino acid position 10 and an amino acid is substituted at one or more amino acid positions selected from positions 28, 32, and 34 of SEQ ID NO: 3 or SEQ ID NO: 4.
2. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
3. The mutant Factor VII or Vila polypeptide of claim 1 , wherein said modified GLA domain comprises an amino acid substitution at position 32.
4. The mutant Factor VII or VIIa polypeptide of claim 3 , wherein said modified GLA domain comprises a glutamic acid residue substituted at position 32.
5. The mutant Factor VII or VIIa polypeptide of claim 1 , wherein said modified GLA domain comprises an amino acid substitution at position 34.
6. The mutant Factor VII or VIIa polypeptide of claim 3 , wherein said modified GLA domain further comprises an amino acid substitution at position 34.
7. The mutant Factor VII or VIIa polypeptide of claim 4 , wherein said modified GLA domain further comprises an amino acid substitution at position 34.
8. The mutant Factor VII or VIIa polypeptide of claim 7 , wherein said modified GLA domain further comprises a glutamic acid residue substituted at position 34.
9. The mutant Factor VII or VIIa polypeptide of claim 1 , further comprising a tyrosine or glycine residue inserted at position 4.
10. The mutant Factor VII or VIIa polypeptide of claim 3 , further comprising a tyrosine or glycine residue inserted at position 4.
11. The mutant Factor VII or VIIa polypeptide of claim 1 , wherein said modified GLA domain comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 4 wherein a glutamine residue is substituted at amino acid position 10 and amino acids are substituted at two or more amino acid positions selected from positions 28, 32, and 34.